Abstract
Introduction: Many controversies exist regarding the appropriate management of patients with upper tract urothelial carcinoma (UTUC), including staging, surgical management, use of systemic therapy, and prevention of bladder recurrence. Due to the rarity of this condition, high-level evidence is often lacking and in many cases guidelines are extrapolated from existing evidence on urothelial bladder cancer. Areas covered: This review paper summarizes the evidence on proper diagnosis and staging, surgical techniques, prevention of bladder recurrences, the use of local or systemic treatments in both neoadjuvant and adjuvant settings as well as special consideration for hereditary UTUC. Expert commentary: UTUC is a rare malignancy and slow progress is being made in the acquisition of high-quality evidence in this field. Treatments that facilitate preservation of the kidney are being explored such as advanced endoscopic techniques or partial resection of ureteral disease with seemingly acceptable oncological results. Further prospective evidence is needed.
Original language | English (US) |
---|---|
Pages (from-to) | 765-774 |
Number of pages | 10 |
Journal | Expert Review of Anticancer Therapy |
Volume | 18 |
Issue number | 8 |
DOIs | |
State | Published - Aug 3 2018 |
Keywords
- Upper tract urothelial carcinoma
- lynch syndrome
- surgical management
- transitional carcinoma
- urothelial carcinoma
ASJC Scopus subject areas
- Oncology
- Pharmacology (medical)